Faul MM - Search Results

1

Antiangiogenic effects of a protein kinase Cbeta-selective small molecule.

Teicher BA, Alvarez E, Menon K, Esterman MA, Considine E, Shih C, Faul MM. Teicher BA, et al. Among authors: faul mm. Cancer Chemother Pharmacol. 2002 Jan;49(1):69-77. doi: 10.1007/s00280-001-0386-2. Cancer Chemother Pharmacol. 2002. PMID: 11855754

2

Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts.

Teicher BA, Menon K, Alvarez E, Shih C, Faul MM. Teicher BA, et al. Among authors: faul mm. Invest New Drugs. 2002 Aug;20(3):241-51. doi: 10.1023/a:1016297611825. Invest New Drugs. 2002. PMID: 12201487

3

An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.

Keyes K, Cox K, Treadway P, Mann L, Shih C, Faul MM, Teicher BA. Keyes K, et al. Among authors: faul mm. Cancer Res. 2002 Oct 1;62(19):5597-602. Cancer Res. 2002. PMID: 12359773

4

Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts.

Teicher BA, Menon K, Alvarez E, Liu P, Shih C, Faul MM. Teicher BA, et al. Among authors: faul mm. In Vivo. 2001 May-Jun;15(3):185-93. In Vivo. 2001. PMID: 11491013

5

Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in murine lewis lung carcinoma and human Calu-6 non-small-cell lung carcinoma xenografts.

Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM. Teicher BA, et al. Among authors: faul mm. Cancer Chemother Pharmacol. 2001 Dec;48(6):473-80. doi: 10.1007/s002800100372. Cancer Chemother Pharmacol. 2001. PMID: 11800028

6

Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts.

Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM. Teicher BA, et al. Among authors: faul mm. Anticancer Res. 2001 Sep-Oct;21(5):3175-84. Anticancer Res. 2001. PMID: 11848470

7

Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts.

Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M. Teicher BA, et al. Clin Cancer Res. 2001 Mar;7(3):634-40. Clin Cancer Res. 2001. PMID: 11297259

8

Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors.

Zhu G, Conner SE, Zhou X, Shih C, Li T, Anderson BD, Brooks HB, Campbell RM, Considine E, Dempsey JA, Faul MM, Ogg C, Patel B, Schultz RM, Spencer CD, Teicher B, Watkins SA. Zhu G, et al. Among authors: faul mm. J Med Chem. 2003 May 22;46(11):2027-30. doi: 10.1021/jm0256169. J Med Chem. 2003. PMID: 12747775

9

1,7-annulated indolocarbazoles as cyclin-dependent kinase inhibitors.

Al-awar RS, Ray JE, Hecker KA, Huang J, Waid PP, Shih C, Brooks HB, Spencer CD, Watkins SA, Patel BR, Stamm NB, Ogg CA, Schultz RM, Considine EL, Faul MM, Sullivan KA, Kolis SP, Grutsch JL, Joseph S. Al-awar RS, et al. Among authors: faul mm. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3217-20. doi: 10.1016/j.bmcl.2004.03.105. Bioorg Med Chem Lett. 2004. PMID: 15149678

10

Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors.

Al-awar RS, Ray JE, Hecker KA, Joseph S, Huang J, Shih C, Brooks HB, Spencer CD, Watkins SA, Schultz RM, Considine EL, Faul MM, Sullivan KA, Kolis SP, Carr MA, Zhang F. Al-awar RS, et al. Among authors: faul mm. Bioorg Med Chem Lett. 2004 Aug 2;14(15):3925-8. doi: 10.1016/j.bmcl.2004.05.088. Bioorg Med Chem Lett. 2004. PMID: 15225699

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters